Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.14 | N/A | +26.32% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.14 | N/A | +26.32% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding current market conditions. They acknowledged the need for a strategic reassessment.
Management highlighted ongoing challenges in the market.
They emphasized the need for strategic adjustments moving forward.
Nektar Therapeutics reported a narrower-than-expected loss per share, but did not provide revenue figures or future guidance. The stock fell by 4.27%, likely reflecting investor concerns about the lack of revenue details and overall market challenges. The cautious tone from management may indicate a more challenging environment ahead.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ROCKET COMPANIES CLA A
Nov 4, 2013